TCL Archive Dramatic responses to Iressa prompted further bench research. Results have limited clinical relevance, for now, but findings may explain failure of INTACT studies. April 30, 2004
TCL Archive NCI Chips In $2 Million For AACR Meeting; Advisors, Senior Staff Not Consulted. June 20, 2003
TCL Archive ODAC Votes to Nix Amgen’s Drug Xgeva For Proposed Prostate Cancer Indication February 17, 2012
